Lantheus Holdings Inc (LNTH)
NASDAQ:LNTH
Want to see LNTH full AI Analyst Report?
LNTH Stock Chart & Stats
$83.82
-$2.32(-2.39%)
At close: 4:00 PM EST
$83.82
-$2.32(-2.39%)
Day’s Range― - ―
52-Week Range$47.25 - $107.99
Previous CloseN/A
Volume177.90K
Average Volume (3M)1.07M
Market Cap
$6.81B
Enterprise Value$6.97B
Total Cash (Recent Filing)$498.58M
Total Debt (Recent Filing)$625.75M
Price to Earnings (P/E)24.4
Beta0.62
Next Earnings
Jul 30, 2026EPS Estimate
1.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.21
Shares Outstanding65,106,080
10 Day Avg. Volume845,752
30 Day Avg. Volume1,073,584
Financial Highlights & Ratios
PEG Ratio-0.82
Price to Book (P/B)4.12
Price to Sales (P/S)2.91
P/FCF Ratio12.69
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue4.50
Enterprise Value/Gross Profit7.45
Enterprise Value/Ebitda14.74
Forecast
1Y Price Target
$106.00Price Target Upside26.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)5.33
Revenue Forecast (FY)$1.47B
Bulls Say, Bears Say
Bulls Say
Deleveraged Balance SheetLantheus shows a material deleveraging to near‑zero net leverage in 2025/TTM with equity growth and ROE in the low‑20% range. This durable balance‑sheet strength reduces refinancing and interest risk, expands strategic optionality for M&A or buybacks, and supports sustained investment in launches.
Strong Cash Generation & LiquidityOperating cash flow consistently exceeds net income and free cash flow is robust, providing durable internal funding. Large cash balance, healthy FCF conversion and an undrawn revolver leave capacity to fund commercialization, development, capex, and shareholder returns without stressing liquidity over the medium term.
Product Leadership & TRUVU Supply AdvantageRegulatory approval of PYLARIFY TRUVU (larger batches, better stability) plus volume gains, dominant DEFINITY share and NEUROCEQ expansion underpin durable commercial advantages. Improved manufacturing scale and stability reduce supply constraints and support broader adoption and longer‑term market share resilience.
Bears Say
Oncology Revenue & Pricing PressurePYLARIFY revenue fell year‑over‑year despite higher U.S. volumes, indicating net ASP/price erosion from competitive entrants. Persistent pricing pressure on a core oncology product can materially reduce top‑line and margin predictability over multiple quarters and slows sustainable revenue growth.
Rising Operating Expenses And Margin DilutionA notable step‑up in operating expense rate driven by acquisitions, integration and launch activities compressed operating profit and adjusted income. Realizing synergies can take many quarters; elevated structural opex risks longer‑term margin sustainability absent offsetting revenue gains.
Regulatory & Legal Timing UncertaintyKey assets face regulatory or legal timing risk (review extensions, tentative approvals subject to Hatch‑Waxman stays). Such binary timing uncertainty can defer revenue realization, prolong commercialization costs, and introduce execution risk across multiple reporting periods.
Lantheus News
LNTH FAQ
What was Lantheus Holdings Inc’s price range in the past 12 months?
Lantheus Holdings Inc lowest stock price was $47.25 and its highest was $107.99 in the past 12 months.
What is Lantheus Holdings Inc’s market cap?
Lantheus Holdings Inc’s market cap is $6.81B.
When is Lantheus Holdings Inc’s upcoming earnings report date?
Lantheus Holdings Inc’s upcoming earnings report date is Jul 30, 2026 which is in 43 days.
How were Lantheus Holdings Inc’s earnings last quarter?
Lantheus Holdings Inc released its earnings results on May 07, 2026. The company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.229 by $0.231.
Is Lantheus Holdings Inc overvalued?
According to Wall Street analysts Lantheus Holdings Inc’s price is currently Undervalued.
Does Lantheus Holdings Inc pay dividends?
Lantheus Holdings Inc does not currently pay dividends.
What is Lantheus Holdings Inc’s EPS estimate?
Lantheus Holdings Inc’s EPS estimate is 1.29.
How many shares outstanding does Lantheus Holdings Inc have?
Lantheus Holdings Inc has 65,106,080 shares outstanding.
What happened to Lantheus Holdings Inc’s price movement after its last earnings report?
Lantheus Holdings Inc reported an EPS of $1.46 in its last earnings report, beating expectations of $1.229. Following the earnings report the stock price went up 5.63%.
Which hedge fund is a major shareholder of Lantheus Holdings Inc?
Currently, no hedge funds are holding shares in LNTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lantheus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$106.00 (26.46% Upside)
$106.00 (26.46% Upside)
Blogger Sentiment
Bullish
LNTH Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 80.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.48%
12-Months-Change
Fundamentals
Return on Equity
24.33%
Trailing 12-Months
Asset Growth
14.18%
Trailing 12-Months
Company Description
Lantheus Holdings Inc
Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the Automated Bone Scan Index, a tool for quantifying prostate cancer burden from bone scans; PYLARIFY, designed for visualizing lymph nodes, bone, and soft tissue metastases to detect recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In the therapeutic space, Lantheus provides AZEDRA, a radiopharmaceutical treatment for both adult and pediatric patients, and RELISTOR, a medication addressing opioid-induced constipation. The company's robust development pipeline includes promising innovations such as flurpiridaz F 18, an agent for assessing myocardial blood flow; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in both children and adults; PYLARIFY AI, an AI-powered medical device software for standardized quantitative analysis of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. Lantheus serves a diverse client base, including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group medical practices. They foster strategic collaborations with notable industry partners such as NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, Curium, Bayer AG, CytoDyn Inc., ROTOP, FUJIFILM, Regeneron Pharmaceuticals, Inc., and POINT Biopharma US Inc. Established in 1956, Lantheus Holdings, Inc. maintains its corporate headquarters in North Billerica, Massachusetts.
LNTH Company Deck
LNTH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call contained meaningful positives — regulatory progress with PYLARIFY TRUVU approval, solid cash generation, NEUROCEQ and DEFINITY growth, and a reaffirmed full-year outlook — balanced against near-term profitability pressure driven by lower oncology reported revenue, higher operating expenses from recent acquisitions and investments, competitive and pricing risks in PSMA PET, and regulatory timing uncertainty for some therapeutic assets. Management emphasized disciplined capital allocation and readiness to launch TRUVU, and expects growth acceleration in 2027, but near-term headwinds keep the tone measured.View all LNTH earnings summariesLNTH Revenue Breakdown
65.91% Radiopharmaceutical oncology
30.09% Precision diagnostics
4.00% Strategic Partnerships and other revenue
LNTH Stock 12 Month Forecast
Average Price Target
$106.00
▲(26.46% Upside)
Technical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
HUTCHMED
―
Amneal Pharmaceuticals
―
Ownership Overview
12.63% Insiders
34.97% Mutual Funds
12.75% Other Institutional Investors
10.89% Public Companies and Individual Investors